SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is experiencing intense volatility and social media attention as investors speculate on a major buyout and an imminent short squeeze following a significant increase in short interest and a high-stakes clinical trial readout. The community is sharply divided, with bulls pointing to institutional positioning and potential acquisition catalysts, while bears focus on trial outcome risks and concerns regarding share dilution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on its potential inclusion in the Russell 1000 index, driving significant volume and heightened options activity. The community remains deeply divided between those betting on an imminent short squeeze and others warning that index-related optimism may be a temporary distraction from the company's long-term clinical and regulatory milestones.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing intense debate as investors weigh concerns over SaaS valuations and AI disruption against its role as an enterprise orchestration layer, with community sentiment shifting between aggressive accumulation and frustration over recent volatility. Bullish traders are highlighting institutional insider buying and strategic partnerships as catalysts for a potential reversal, while bearish participants question the sustainability of the company's growth in an era of rapid AI development.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is seeing heightened volatility and debate as community members speculate on a potential price breakout, while others voice concerns regarding historical pump-and-dump patterns and lack of clear communication from the team. Traders are actively tracking technical indicators and volume spikes, with many discussing the risk-to-reward potential of holding the token amidst ongoing market fluctuations.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is surging following the FDA approval of its flagship thyroid eye disease treatment, Lumvoa, which is the first therapy in the class with labeling supported by clinical data for both active and chronic patients. The community is actively discussing the stock's commercial launch potential, its competitive edge over Amgen's Tepezza, and the possibility of a major partnership or acquisition as institutional interest builds.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility driven by rapidly shifting geopolitical headlines between the U.S. and Iran, with community sentiment split between skepticism over potential "fake" peace deals and bullish anticipation for a holiday-week rally. Investors are actively debating the sustainability of the current market structure amid AI-sector rebalancing and recurring weekend war-related news cycles.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is generating intense community debate as investors weigh the company's defensive drone technology against ongoing concerns about management's communication and lack of significant contract revenue. While proponents emphasize the long-term potential of the firm's autonomous maritime and reconnaissance platforms in modern combat, skeptics are actively scrutinizing insider share sales and the impact of continuous dilution on shareholder value.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing heightened volatility as investors grapple with shifting sentiment around AI infrastructure spending, intensified by upcoming memory chip earnings reports and broader concerns over sector cyclicality. The community is actively debating the sustainability of the AI rally, with traders split between aggressively buying dips in semiconductor exposure and shorting the asset in anticipation of a potential sector-wide correction.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as shareholders express frustration over ongoing stock underperformance and the recent departure of its CFO, while active community debate focuses on the company's need for a potential acquisition of oncology-focused assets to revitalize its pipeline. Investors are closely monitoring the healthcare sector for signs of a rotation into value-oriented stocks, contrasting Pfizer's stagnant price action with the aggressive growth seen in peers like Eli Lilly.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors monitor the company's production scaling for its optical engines and upcoming Annual General Meeting, which has become a focal point for updates on customer adoption and potential strategic partnerships. While some community members remain focused on the long-term potential of the company's photonics platform to solve industry bottlenecks, others are expressing frustration over recent stock volatility and the lack of immediate, high-impact news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NCDL Outstanding article that hits the mark on NCDL&#39;s current state. So if you want to refresh your NCDL insights or learn about NCDL from scratch, this is a must read. https://beyondspx.com/quote/NCDL/analysis/ncdl-a-core-middle-market-powerhouse-primed-for-growth

Nuveen Churchill Direct Lending Corp. (NCDL) is a leading business development company (BDC) focused on senior secured loans to private equity-owned U.S. middle market companies, leveraging its deep r...

BeyondSPX

NCDL: A Core Middle Market Powerhouse Primed for Growth - NCDL Stock Analysis

StockTwits Web

Nuveen Churchill Direct Lending Corp

 Outstanding article that hits the mark on NCDL's current state. So if you want to refresh your NCDL insights or learn about NCDL from scratch, this is a must read. 